FDA approves Takeda's Orzeyful, first orexin agonist drug for narcolepsy type 1

The FDA has approved Takeda Pharmaceutical's Orzeyful (oveporexton), making it the first orexin receptor 2 agonist cleared to treat the underlying biology of narcolepsy type 1 in adults. In Phase 3 trials, the twice-daily oral pill significantly improved wakefulness and reduced cataplexy compared to placebo. Analysts estimate the drug could cost up to $250,000 annually per patient, with peak sales reaching $2 billion. A commercial launch is expected within 90 days following a DEA scheduling review.

Orzeyful FDA approval

• ▪Orzeyful is the first orexin receptor 2 agonist to be approved by the FDA and the first drug indicated to treat the full range of narcolepsy type 1 manifestations.
• ▪The U.S. Food and Drug Administration approved Takeda Pharmaceutical's Orzeyful (oveporexton) on August 5, 2026, as an oral treatment for narcolepsy type 1 in adults.

Orexin receptor agonist mechanism

• ▪By activating orexin receptor 2, Orzeyful promotes wakefulness and reduces abnormal rapid eye movement-sleep like phenomena, including sudden muscle weakness known as cataplexy.
• ▪Orzeyful is an oral orexin receptor 2 agonist that selectively stimulates the receptor to restore signaling and address the underlying orexin deficiency associated with narcolepsy type 1.

Narcolepsy type 1 biology

• ▪People living with narcolepsy type 1 experience excessive daytime sleepiness, cataplexy, cognitive symptoms, and disrupted nighttime sleep.
• ▪Narcolepsy type 1 is a rare, chronic neurological disease driven by a loss of orexin neurons and deficiency, affecting an estimated 120,000 people in the United States.

Clinical trial efficacy results

• ▪Patients treated with Orzeyful showed Epworth Sleepiness Scale score improvements of up to 9.8 points versus placebo, bringing patients close to the normal wakefulness range.
• ▪In the Phase 3 FirstLight and RadiantLight clinical trials, Orzeyful demonstrated statistically significant improvements over placebo in excessive daytime sleepiness, cataplexy, and quality of life.
• ▪The most common adverse reactions reported in Phase 3 studies of Orzeyful were insomnia, urinary frequency, urinary urgency, and salivary hypersecretion.

Market pricing expectations

• ▪Jefferies analysts estimate that Orzeyful could cost between $142,000 and over $250,000 per patient annually, with peak net annual sales predicted to reach roughly $2 billion.
• ▪Takeda Pharmaceutical expects that the FDA approval of Orzeyful will not have a significant impact on its consolidated financial forecast for the fiscal year ending March 31, 2027.

DEA scheduling launch timeline

• ▪The Drug Enforcement Administration scheduling review for Orzeyful is expected to be completed within 90 days of the drug's FDA approval.
• ▪Orzeyful must undergo a review by the U.S. Drug Enforcement Administration to determine its controlled substance scheduling classification before it can be commercially launched.